Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.

Takeda M, Sakai K, Hayashi H, Tanaka K, Haratani K, Takahama T, Kato R, Yonesaka K, Nishio K, Nakagawa K.

Lung Cancer. 2019 Nov 3;139:28-34. doi: 10.1016/j.lungcan.2019.10.028. [Epub ahead of print]

PMID:
31710890
2.

U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.

Haratani K, Yonesaka K, Takamura S, Maenishi O, Kato R, Takegawa N, Kawakami H, Tanaka K, Hayashi H, Takeda M, Maeda N, Kagari T, Hirotani K, Tsurutani J, Nishio K, Doi K, Miyazawa M, Nakagawa K.

J Clin Invest. 2019 Oct 29. pii: 126598. doi: 10.1172/JCI126598. [Epub ahead of print]

3.

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI.

Yonesaka K, Tanaka K, Kitano M, Kawakami H, Hayashi H, Takeda M, Sakai K, Nishio K, Doi K, Nakagawa K.

Oncogenesis. 2019 Sep 30;8(10):54. doi: 10.1038/s41389-019-0164-9.

4.

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.

Nonagase Y, Takeda M, Azuma K, Hayashi H, Haratani K, Tanaka K, Yonesaka K, Ishii H, Hoshino T, Nakagawa K.

Thorac Cancer. 2019 Oct;10(10):1928-1935. doi: 10.1111/1759-7714.13166. Epub 2019 Aug 16.

5.

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing.

Sakai K, Takeda M, Shimizu S, Takahama T, Yoshida T, Watanabe S, Iwasa T, Yonesaka K, Suzuki S, Hayashi H, Kawakami H, Nonagase Y, Tanaka K, Tsurutani J, Saigoh K, Ito A, Mitsudomi T, Nakagawa K, Nishio K.

Sci Rep. 2019 Aug 5;9(1):11340. doi: 10.1038/s41598-019-47673-9.

6.

[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.

Takegawa N, Tsurutani J, Kawakami H, Yonesaka K, Kato R, Haratani K, Hayashi H, Takeda M, Nonagase Y, Maenishi O, Nakagawa K.

Int J Cancer. 2019 Dec 15;145(12):3414-3424. doi: 10.1002/ijc.32408. Epub 2019 May 24.

PMID:
31087550
7.

Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis.

Suzuki S, Haratani K, Takahama T, Watanabe S, Takegawa N, Hayashi H, Takeda M, Yonesaka K, Nakagawa K.

J Thorac Oncol. 2019 Mar;14(3):e50-e52. doi: 10.1016/j.jtho.2018.11.012. No abstract available.

PMID:
30782383
8.

Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.

Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K.

Cancer Med. 2019 Mar;8(3):1258-1268. doi: 10.1002/cam4.1995. Epub 2019 Jan 31.

9.

Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells.

Yonesaka K, Kobayashi Y, Hayashi H, Chiba Y, Mitsudomi T, Nakagawa K.

Oncol Rep. 2019 Feb;41(2):1059-1066. doi: 10.3892/or.2018.6881. Epub 2018 Nov 22.

PMID:
30483795
10.

Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.

Watanabe S, Hayashi H, Haratani K, Shimizu S, Tanizaki J, Sakai K, Kawakami H, Yonesaka K, Tsurutani J, Togashi Y, Nishio K, Ito A, Nakagawa K.

Cancer Sci. 2019 Jan;110(1):52-60. doi: 10.1111/cas.13860. Epub 2018 Nov 27.

11.

An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.

Yonesaka K, Takegawa N, Watanabe S, Haratani K, Kawakami H, Sakai K, Chiba Y, Maeda N, Kagari T, Hirotani K, Nishio K, Nakagawa K.

Oncogene. 2019 Feb;38(9):1398-1409. doi: 10.1038/s41388-018-0517-4. Epub 2018 Oct 9.

PMID:
30302022
12.

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.

Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, Kato S, Maenishi O, Sakai K, Chiba Y, Okabe T, Kudo K, Hasegawa Y, Kaneda H, Yamato M, Hirotani K, Miyazawa M, Nishio K, Nakagawa K.

Clin Cancer Res. 2018 Jun 1;24(11):2653-2664. doi: 10.1158/1078-0432.CCR-17-2852. Epub 2018 Mar 12.

13.

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.

Tanizaki J, Haratani K, Hayashi H, Chiba Y, Nakamura Y, Yonesaka K, Kudo K, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Ito A, Nakagawa K.

J Thorac Oncol. 2018 Jan;13(1):97-105. doi: 10.1016/j.jtho.2017.10.030. Epub 2017 Nov 21.

14.

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.

Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K.

JAMA Oncol. 2018 Mar 1;4(3):374-378. doi: 10.1001/jamaoncol.2017.2925.

15.

T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer.

Watanabe S, Yoshida T, Kawakami H, Takegawa N, Tanizaki J, Hayashi H, Takeda M, Yonesaka K, Tsurutani J, Nakagawa K.

Mol Cancer Ther. 2017 Nov;16(11):2563-2571. doi: 10.1158/1535-7163.MCT-17-0351. Epub 2017 Aug 24.

16.

DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.

Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J.

Int J Cancer. 2017 Oct 15;141(8):1682-1689. doi: 10.1002/ijc.30870. Epub 2017 Jul 12.

17.

Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).

Miura Y, Sukawa Y, Hironaka S, Mori M, Nishikawa K, Tokunaga S, Okuda H, Sakamoto T, Taku K, Nishikawa K, Moriwaki T, Negoro Y, Kimura Y, Uchino K, Shinozaki K, Shinozaki H, Musha N, Yoshiyama H, Tsuda T, Miyata Y, Sugimoto N, Shirakawa T, Ito M, Yonesaka K, Yoshimura K, Boku N, Nosho K, Takano T, Hyodo I.

Gastric Cancer. 2018 Jan;21(1):84-95. doi: 10.1007/s10120-017-0725-6. Epub 2017 May 11.

PMID:
28497176
18.

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K.

Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183.

PMID:
28407039
19.

HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy.

Takegawa N, Yonesaka K.

Clin Colorectal Cancer. 2017 Dec;16(4):247-251. doi: 10.1016/j.clcc.2017.03.001. Epub 2017 Mar 9. Review.

PMID:
28363756
20.

Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.

Yonesaka K, Hirotani K, von Pawel J, Dediu M, Chen S, Copigneaux C, Nakagawa K.

Lung Cancer. 2017 Mar;105:1-6. doi: 10.1016/j.lungcan.2016.12.018. Epub 2017 Jan 9.

PMID:
28236978
21.

Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.

Shimizu T, Yonesaka K, Hayashi H, Iwasa T, Haratani K, Yamada H, Ohwada S, Kamiyama E, Nakagawa K.

Cancer Chemother Pharmacol. 2017 Mar;79(3):489-495. doi: 10.1007/s00280-016-3231-3. Epub 2017 Jan 31.

22.

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.

Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J.

Oncotarget. 2016 Dec 20;7(51):84860-84871. doi: 10.18632/oncotarget.12743.

23.

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.

Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K.

Cancer Sci. 2016 Dec;107(12):1843-1850. doi: 10.1111/cas.13098.

24.

Spontaneous pneumothorax due to bronchopleural fistula following reirradiation for locoregionally recurrent squamous cell lung cancer.

Ota T, Suzumura T, Sugiura T, Hasegawa Y, Yonesaka K, Makihara M, Tsukuda H, Tada T, Fukuoka M.

Clin Case Rep. 2016 Apr 1;4(5):481-5. doi: 10.1002/ccr3.547. eCollection 2016 May.

25.

HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy.

Kawakami H, Yonesaka K.

Recent Pat Anticancer Drug Discov. 2016;11(3):267-74. Review.

PMID:
27086600
26.

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.

Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I.

Cancer. 2016 Apr 1;122(7):1050-9. doi: 10.1002/cncr.29893. Epub 2016 Feb 1.

27.

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.

Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K.

Oncotarget. 2016 Jan 19;7(3):3453-60. doi: 10.18632/oncotarget.6498.

28.

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer.

Yonesaka K, Takegawa N, Satoh T, Ueda H, Yoshida T, Takeda M, Shimizu T, Chiba Y, Okamoto I, Nishio K, Tamura T, Nakagawa K.

PLoS One. 2015 Nov 16;10(11):e0143132. doi: 10.1371/journal.pone.0143132. eCollection 2015.

29.

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.

Yonesaka K, Kudo K, Nishida S, Takahama T, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Okamoto I, Nishio K, Nakagawa K.

Oncotarget. 2015 Oct 20;6(32):33602-11. doi: 10.18632/oncotarget.5286.

30.

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.

Yonesaka K, Hirotani K, Kawakami H, Takeda M, Kaneda H, Sakai K, Okamoto I, Nishio K, Jänne PA, Nakagawa K.

Oncogene. 2016 Feb 18;35(7):878-86. doi: 10.1038/onc.2015.142. Epub 2015 May 11.

PMID:
25961915
31.

Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer.

Yonesaka K, Satoh T, Ueda S, Yoshida T, Takeda M, Shimizu T, Okamoto I, Nishio K, Tamura T, Nakagawa K.

Anticancer Res. 2015 Mar;35(3):1683-9.

PMID:
25750328
32.

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.

Kawakami H, Okamoto I, Yonesaka K, Okamoto K, Shibata K, Shinkai Y, Sakamoto H, Kitano M, Tamura T, Nishio K, Nakagawa K.

Oncotarget. 2014 Dec 15;5(23):11847-56.

33.

Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.

Yonesaka K, Suzumura T, Tsukuda H, Hasegawa Y, Ozaki T, Sugiura T, Fukuoka M.

Anticancer Res. 2014 Sep;34(9):5211-5.

PMID:
25202117
34.

Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia.

Suzumura T, Yonesaka K, Tsukuda H, Fukuoka M.

BMJ Case Rep. 2014 Mar 13;2014. pii: bcr2013202705. doi: 10.1136/bcr-2013-202705.

35.

Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.

Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, Greulich H, Johnson BE, Eck MJ, Jänne PA, Wong KK, Meyerson M.

Cancer Res. 2013 Nov 15;73(22):6770-9. doi: 10.1158/0008-5472.CAN-13-1145. Epub 2013 Sep 24.

36.

A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer.

Hasegawa Y, Okamoto I, Takezawa K, Miyazaki M, Tsurutani J, Yonesaka K, Morinaga R, Tsuya A, Terashima M, Kudoh T, Azuma K, Kurata T, Nishikawa T, Fukuoka M, Nishimura Y, Nakagawa K.

Invest New Drugs. 2013 Jun;31(3):599-604. doi: 10.1007/s10637-012-9833-7. Epub 2012 May 24.

PMID:
22623066
37.

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA.

Sci Transl Med. 2011 Sep 7;3(99):99ra86. doi: 10.1126/scitranslmed.3002442.

38.

Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis.

Kawakami H, Sugioka K, Yonesaka K, Satoh T, Shimomura Y, Nakagawa K.

J Clin Oncol. 2011 Aug 10;29(23):e678-9. doi: 10.1200/JCO.2011.35.0694. Epub 2011 Jun 20. No abstract available.

PMID:
21690478
39.

High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.

Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, Yonesaka K, Hayashi H, Makimura C, Okamoto K, Kiyota H, Tsurutani J, Miyazaki M, Yoshinaga M, Fujiwara K, Yamazoe Y, Moriyama K, Tsubaki M, Chiba Y, Nishida S, Nakagawa K.

Int J Clin Oncol. 2011 Jun;16(3):244-9. doi: 10.1007/s10147-010-0170-6. Epub 2011 Jan 18.

PMID:
21243395
40.

Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.

Okamoto I, Takeda K, Daga H, Miyazaki M, Yonesaka K, Kiyota H, Tsurutani J, Ueda S, Ichikawa Y, Takeda M, Sekiguchi R, Tominaga K, Enatsu S, Nambu Y, Nakagawa K.

Lung Cancer. 2010 Nov;70(2):168-73. doi: 10.1016/j.lungcan.2010.02.007. Epub 2010 Mar 16.

PMID:
20236726
41.

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.

Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA.

Oncogene. 2010 Apr 22;29(16):2346-56. doi: 10.1038/onc.2009.526. Epub 2010 Feb 1.

42.

Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.

Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K.

Cancer Res. 2009 Aug 15;69(16):6515-21. doi: 10.1158/0008-5472.CAN-09-1076. Epub 2009 Jul 28.

43.

Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.

Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Jänne PA.

Clin Cancer Res. 2008 Nov 1;14(21):6963-73. doi: 10.1158/1078-0432.CCR-08-0957.

44.

Down-regulation of survivin by ultraviolet C radiation is dependent on p53 and results in G(2)-M arrest in A549 cells.

Ikeda M, Okamoto I, Tamura K, Satoh T, Yonesaka K, Fukuoka M, Nakagawa K.

Cancer Lett. 2007 Apr 18;248(2):292-8. Epub 2006 Sep 7.

PMID:
16959403
45.

Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.

Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M, Nakagawa K.

Int J Cancer. 2006 Feb 15;118(4):812-20.

Supplemental Content

Loading ...
Support Center